patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus control - for COVID 19 all comers
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.93 [0.85, 1.01]< 1 21% 6 studies (6/-) 95.1 % some concern not evaluable moderate crucial - death or transfer to ICU 0.75 [0.43, 1.31]< 1 18% 2 studies (2/-) 84.3 % low not evaluable high crucial - deaths 0.89 [0.78, 1.02]< 1 37% 8 studies (8/-) 95.6 % some concern not evaluable moderate crucial 1 deaths (time to event analysis only) 0.56 [0.38, 0.84]< 1 0% 2 studies (2/-) 99.8 % some concern not evaluable moderate crucial - clinical deterioration 1.10 [0.60, 2.01]< 1 0% 2 studies (2/-) 37.9 % low not evaluable high important - clinical improvement 1.21 [1.08, 1.36]> 1 0% 5 studies (5/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.31 [0.61, 2.83]> 1 0% 2 studies (2/-) 75.5 % some concern not evaluable moderate important - clinical improvement (28-day) 1.35 [1.03, 1.76]> 1 0% 1 study (1/-) 98.7 % NA not evaluable important - clinical improvement (time to event analysis only) 1.24 [1.10, 1.41]> 1 0% 3 studies (3/-) 100.0 % some concern not evaluable moderate important - death or ventilation 0.90 [0.81, 0.99]< 1 0% 2 studies (2/-) 98.2 % some concern not evaluable moderate important - hospital discharge 0.64 [0.37, 1.11]> 1 0% 1 study (1/-) 5.6 % NA not evaluable important - hospitalization 1.63 [0.94, 2.85]< 1 0% 1 study (1/-) 4.2 % NA not evaluable important - mechanical ventilation 1.07 [0.69, 1.67]< 1 41% 3 studies (3/-) 38.2 % some concern not evaluable moderate important - mechanical ventilation (time to event analysis only) 0.69 [0.14, 3.42]< 1 0% 1 study (1/-) 67.5 % NA not evaluable important - viral clearance 1.03 [0.15, 6.91]> 1 45% 2 studies (2/-) 51.3 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 1.78 [1.06, 3.00]> 1 0% 1 study (1/-) 98.5 % NA not evaluable important - viral clearance by day 14 0.18 [0.01, 4.75]> 1 0% 1 study (1/-) 15.7 % NA not evaluable important - ICU admission 0.92 [0.43, 1.99]< 1 0% 3 studies (3/-) 58.3 % some concern not evaluable moderate non important - recovery 1.18 [0.87, 1.61]> 1 0% 1 study (1/-) 85.4 % NA not evaluable non important - 00 serious adverse events 1.05 [0.59, 1.86]< 1 62% 3 studies (3/-) 43.3 % some concern not evaluable moderate important - adverse events 0.80 [0.43, 1.51]< 1 0% 1 study (1/-) 75.3 % NA not evaluable non important - deep vein thrombosis 0.64 [0.23, 1.81]< 1 0% 1 study (1/-) 80.0 % NA not evaluable non important - elevated liver enzymes 0.67 [0.38, 1.18]< 1 0% 1 study (1/-) 91.8 % NA not evaluable non important - hyperbilirubinemia 0.84 [0.30, 2.34]< 1 0% 1 study (1/-) 62.9 % NA not evaluable non important - pulmonary embolism 0.96 [0.19, 4.80]< 1 0% 1 study (1/-) 51.7 % NA not evaluable non important - renal impairment 1.02 [0.64, 1.61]< 1 0% 1 study (1/-) 47.2 % NA not evaluable non important -
LoD: level of statistical demonstration:
